Welcome to our dedicated page for BIOCRYST PHARMACEUTICALS SEC filings (Ticker: BCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCryst Pharmaceuticals, Inc. SEC filings document the company's commercial rare-disease business, including ORLADEYO® results, revenue guidance, pricing disclosures, and financial results furnished on Form 8-K. The filings also describe pipeline and business-development matters involving HAE programs, including navenibart licensing and the completed acquisition of Astria Therapeutics as a BioCryst subsidiary.
BioCryst's filings further cover financing and capital-structure matters, including term-loan arrangements, as well as proxy disclosures on board elections, executive compensation, equity awards, committee structure, and shareholder voting matters. Material-event reports and proxy statements provide the formal record for governance changes, strategic transactions, and Regulation FD disclosures.
BioCryst Pharmaceuticals is shutting down its internal discovery programs and closing its Discovery Center of Excellence in Birmingham, Alabama by the end of 2026, shifting its research strategy toward external innovation to build its rare disease pipeline.
The company now expects full-year 2026 non-GAAP operating expenses of $420–$440 million, lower than prior guidance of $450–$470 million, while reaffirming 2026 revenue guidance for ORLADEYO and total company revenue. BioCryst highlighted two key clinical programs: the Phase 3 ALPHA-ORBIT trial of navenibart in hereditary angioedema, with top-line 6- and 12‑month efficacy data expected in Q3 2027, and BCX17725 in Netherton syndrome, with proof‑of‑concept data expected by year‑end 2026.
The company has also resolved a manufacturing delay for ORLADEYO oral pellets for pediatric patients and expects product availability in early August 2026.
BIOCRYST PHARMACEUTICALS INC director Jill C. Milne received equity awards as part of non‑employee director compensation. She was granted 15,294 shares of Common Stock as Restricted Stock Units that will vest on the first anniversary of the June 11, 2026 grant date.
She also received an automatic grant of options to purchase 33,540 shares of Common Stock at an exercise price of $8.50 per share, exercisable until June 11, 2036. Following the RSU grant, she holds 31,938 Common Stock shares directly. These are compensation-related awards rather than open-market purchases.
BIOCRYST PHARMACEUTICALS INC director Steven K. Galson reported equity awards and updated holdings. He received 15,294 shares of Common Stock as a grant of Restricted Stock Units under the company’s Non-Employee Director Compensation Policy, with these units scheduled to vest on the first anniversary of the grant date.
He also received an automatic stock option grant covering 33,540 shares of Common Stock at an exercise price of $8.50 per share, exercisable from June 11, 2027 and expiring June 11, 2036. Following these awards, he holds 27,794 Common shares directly and 58,371 Common shares indirectly through a living trust. The filing reflects compensation-related grants rather than open-market purchases or sales.
BIOCRYST PHARMACEUTICALS director Alan G. Levin received equity awards as part of non-employee director compensation. He was granted 15,294 shares of Common Stock as Restricted Stock Units that will vest on the first anniversary of the grant date. He also received an automatic stock option grant for 33,540 shares of Common Stock at an exercise price of $8.5000 per share, expiring on June 11, 2036. Following these awards, he directly holds 79,565 shares of Common Stock.
BIOCRYST PHARMACEUTICALS INC director equity awards: Director Steven Frank received a grant of 15,294 shares of Common Stock as Restricted Stock Units under the company’s Non-Employee Director Compensation Policy. These RSUs will vest on the first anniversary of the June 11, 2026 grant date.
Frank also received an automatic non-employee director stock option grant covering 33,540 shares of Common Stock at an exercise price of $8.50 per share, exercisable from June 11, 2027 and expiring June 11, 2036. After these awards, he directly holds 35,459 shares of Common Stock.
BioCryst Pharmaceuticals director Machelle Sanders received new equity awards consisting of restricted stock units and stock options. She was granted 15,294 shares of Common Stock as Restricted Stock Units under the company’s Non-Employee Director Compensation Policy, which will vest on the first anniversary of the grant date.
She also received an automatic stock option grant covering 33,540 shares of Common Stock at an exercise price of $8.50 per share, expiring on June 11, 2036. After these awards, she directly holds 45,936 shares of Common Stock. These are compensation-related grants, not open-market purchases or sales.
BIOCRYST PHARMACEUTICALS INC director Vincent Milano reported equity compensation awards rather than open-market trades. He received 15,294 shares of Common Stock as a grant, increasing his directly held stake to 108,483 shares. These were granted at no cash purchase price as part of his director compensation.
Milano was also granted an Automatic Stock Option for 33,540 shares of Common Stock with a conversion or exercise price of $8.50 per share. According to the company’s Non-Employee Director Compensation Policy, the Restricted Stock Units vest on the first anniversary of the grant date, and the stock options expire in 2036, reflecting routine, policy-based director compensation.
BioCryst Pharmaceuticals director Jon P. Stonehouse reported routine equity compensation grants. He received 15,294 shares of Common Stock as a grant, increasing his direct holdings to 1,339,775 shares. These shares were granted at no cash cost as part of his non-employee director compensation.
He was also granted an Automatic Stock Option for 33,540 shares of Common Stock at an exercise price of $8.50 per share, expiring on June 11, 2036. Footnotes explain these are automatic non-employee director grants of Restricted Stock Units and stock options under BioCryst’s Director Compensation Policy. Two family irrevocable trusts associated with his wife each report indirect holdings of 40,000 Common Stock shares.
BioCryst Pharmaceuticals director Amy E. McKee received equity compensation awards. On the grant date, she acquired 15,294 shares of common stock through a restricted stock unit grant under the company’s Non-Employee Director Compensation Policy. Following this grant, she directly holds 47,177 common shares.
She was also granted an automatic stock option covering 33,540 shares of common stock at an exercise price of $8.50 per share, exercisable until June 11, 2036. The restricted stock units will vest on the first anniversary of the grant date, aligning her compensation with long-term shareholder interests.
BIOCRYST PHARMACEUTICALS INC director Theresa Heggie reported equity awards received as part of non-employee director compensation. She acquired 15,294 shares of Common Stock through a grant of Restricted Stock Units that will vest on the first anniversary of the grant date. She also received an automatic stock option grant covering 33,540 shares of Common Stock at an exercise price of $8.50 per share, expiring on June 11, 2036. Following these awards, she directly holds 80,646 shares of Common Stock. These awards were made under the company’s Non-Employee Director Compensation Policy and represent routine compensation, not open-market buying or selling.